1-4 of 4
Marays Veliz
Close
Save search
Sort by
Journal Articles

Correlative Analysis of T Cell Subpopulations and CD20 Expression In a Phase II Study of Lenalidomide In Combination with Rituximab In Patients with Relapsed or Refractory CLL/SLL

Free
Marays Veliz, M.D., John Powers, Ling Zhang, MD, Enrique Santana, RN, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Mohamed Kharfan-Dabaja, MD, Sara Tinsley, ARNP, Darcie Deaver, Eduardo M. Sotomayor, MD, Javier Pinilla-Ibarz, MD
Journal: Blood
Blood (2010) 116 (21): 4630.
https://doi.org/10.1182/blood.V116.21.4630.4630
Published: 2010
Journal Articles

Lymphoplasmacytic Differentiation Associated with Lenalidomide Therapy in Patients with Chronic Lymphocytic Leukemia.

Free
Marays Veliz, MD, Lynn C. Moscinski, MD, Ling Zhang, MD, Eduardo M. Sotomayor, MD, Javier Pinilla-Ibarz, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 4412.
https://doi.org/10.1182/blood.V114.22.4412.4412
Published: 2009
Journal Articles

Hypercalcemia Following Treatment with Lenalidomide in Chronic Lymphocytic Leukemia (CLL).

Free
Bijal D. Shah, MD, Marays Veliz, MD, Ricardo Santana, Jeffrey E Lancet, MD, John J. Powers, B.S., Jason A Dubovsky, B.S., Sara Tinsley, Darcie Deaver, ANP, MS, Eduardo M. Sotomayor, MD, Javier Pinilla, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 4413.
https://doi.org/10.1182/blood.V114.22.4413.4413
Published: 2009
Journal Articles

Phase II Study of Lenalidomide in Combination with Rituximab for Patients with CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab. Interim Analysis.

Free
Marays Veliz, MD, Ricardo Santana, Jeffrey E Lancet, MD, Rami S. Komrokji, MD, Mohamed A Kharfan-Dabaja, MD, John J. Powers, B.S., Jason A Dubovsky, B.S., Sara Tinsley, Darcie Deaver, ANP, MS, Eduardo M. Sotomayor, MD, Javier Pinilla-Ibarz, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2376.
https://doi.org/10.1182/blood.V114.22.2376.2376
Published: 2009